Filing Analysis
Atea Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the three months ended June 30, 2026. The filing is a routine disclosure of quarterly earnings via press release.
📋 Key Facts
- Report date: August 12, 2026
- Reporting period: Three months ended June 30, 2026
- The company issued a press release (Exhibit 99.1) containing financial results and other matters.
- Signed by Andrea Corcoran, CFO and Executive Vice President.
Atea Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ending September 30, 2025.
📋 Key Facts
- The filing relates to Item 2.02: Results of Operations and Financial Condition.
- The company issued a press release on November 12, 2025, regarding financial results for the three months ended September 30, 2025.
- The press release is furnished as Exhibit 99.1.
Atea Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly financial results for the three months ended June 30, 2025. The filing serves as a formal announcement of the company's recent operational and financial performance.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Three months ended June 30, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Signed by Andrea Corcoran, CFO and Executive Vice President
Atea Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders on June 20, 2025. The meeting resulted in the election of three Class II directors and the ratification of KPMG LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on June 20, 2025.
- Quorum reached with 74,981,407 shares (approx. 87.6% of outstanding common stock).
- Bruno Lucidi, Polly Murphy, and Bruce Polsky elected as Class II Directors to serve until the 2028 annual meeting.
- KPMG LLP ratified as independent registered public accounting firm for the year ending December 31, 2025.
- Advisory (non-binding) vote on executive compensation was approved.
Atea Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly financial results for the three months ended March 31, 2025. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Report date: May 12, 2025
- Reporting period: Three months ended March 31, 2025
- The filing includes Exhibit 99.1 containing the press release with financial results.
- The information under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
Atea Pharmaceuticals has entered into a settlement agreement with Bradley L. Radoff and JEC II Associates to resolve a proxy contest, resulting in the withdrawal of director nominations and the appointment of Howard H. Berman, Ph.D. as a new Class III director. The company also announced a $25 million share repurchase program and reported significant cash reserves.
🚩 Red Flags
- Resolution of a proxy contest indicates recent significant internal governance friction/activist pressure.
- The presence of 'standstill restrictions' and 'voting commitments' confirms the existence of an activist shareholder influence.
📋 Key Facts
- Settlement reached with Radoff-JEC Signatories on April 16, 2025, resolving the threat of a proxy contest for Class II director seats.
- Howard H. Berman, Ph.D. appointed as Class III director (effective after 2025 Annual Meeting) and will serve as a Board observer immediately.
- Franklin Berger announced retirement from the Board effective at the end of his term in 2027.
- Radoff-JEC Signatories are subject to standstill restrictions and voting commitments until either 30 days prior to the 2026 Annual Meeting nomination deadline or 120 days prior to the first anniversary of the 2025 Annual Meeting.
- Board approved a $25.0 million share repurchase program to be funded from existing cash/marketable securities.
- Cash, cash equivalents, and marketable securities totaled $425.4 million as of March 31, 2025 (preliminary estimate).
Atea Pharmaceuticals announced that Driver Opportunity Partners III has withdrawn its nomination of J. Abbott R. Cooper for election to the Company’s Board of Directors at the upcoming 2025 Annual Meeting.
📋 Key Facts
- Driver Opportunity Partners III withdrew its notice to nominate J. Abbott R. Cooper on March 31, 2025.
- J. Abbott R. Cooper will no longer stand for election at the 2025 Annual Meeting of Stockholders.
- The company intends to file a definitive proxy statement (Schedule 14A) regarding its solicitation of proxies.
Atea Pharmaceuticals announced the closing of the nomination window for its 2025 Annual Meeting. The company received several director nominations from external parties, including Bradley L. Radoff and Driver Opportunity Partners III LP.
🚩 Red Flags
- Proxy contest/Director nominations from external parties often indicate shareholder dissatisfaction or activist involvement, though not explicitly labeled as such here.
📋 Key Facts
- The window for stockholder nominations for the 2025 Annual Meeting closed on March 23, 2025.
- Bradley L. Radoff nominated Howard H. Berman, James P. Flynn, and Michael Torok.
- Driver Opportunity Partners III LP nominated J. Abbott R. Cooper.
- The Nominating and Corporate Governance Committee will evaluate these candidates.
- A definitive proxy statement (Schedule 14A) with a 'white' proxy card is expected to be filed ahead of the meeting.
Atea Pharmaceuticals, Inc. issued an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 6, 2025
- Reporting period: Q4 and Full Year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18.
Atea Pharmaceuticals, Inc. announced the election of Arthur Kirsch to its Board of Directors as a Class I director, effective February 20, 2025.
📋 Key Facts
- Arthur Kirsch elected as Class I Director on February 20, 2025.
- Mr. Kirsch is a Senior Advisor to Alvarez & Marsal’s Life Sciences Industry Group.
- Compensation includes an annual cash retainer of $45,000 and certain equity awards.
- Initial equity grant: option to purchase 164,800 shares of common stock, vesting in 36 equal monthly installments.
- Mr. Kirsch has extensive board experience with companies including Liquidia Technologies (LQDA), Kadmon Holdings, and Immunomedics.
Atea Pharmaceuticals issued a press release announcing its preliminary unaudited cash, cash equivalents, and marketable securities balance as of December 31, 2024. The company noted that these figures are estimates subject to change upon completion of year-end audit procedures.
🚩 Red Flags
- Information is unaudited and subject to change upon completion of financial closing procedures
📋 Key Facts
- Report date: January 13, 2025
- Subject matter: Preliminary unaudited cash and marketable securities balance as of Dec 31, 2024
- The information is based on preliminary estimates and has not been audited by independent public accounting firm
- Full details are contained in Exhibit 99.1 (press release)
Atea Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the three months ended September 30, 2024. The filing serves as a formal notice that a press release containing these results has been issued.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Three months ended September 30, 2024
- The filing includes Exhibit 99.1 (Press Release) regarding financial results and other matters.
- Signed by Andrea Corcoran, CFO and Executive Vice President.
Atea Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the three months ended June 30, 2024. The filing serves as a formal announcement of the release of quarterly earnings data.
📋 Key Facts
- Report date: August 7, 2024
- Reporting period: Three months ended June 30, 2024
- The company issued a press release (Exhibit 99.1) containing financial results and other matters.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18.
Atea Pharmaceuticals, Inc. held its 2024 Annual Meeting of Stockholders on June 21, 2024. The meeting resulted in the election of two directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 21, 2024.
- Quorum reached with 74,365,479 shares present (approx. 88.29% of outstanding common stock).
- Franklin Berger and Jean-Pierre Sommadossi, Ph.D. were elected to the Board of Directors.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Shareholders approved executive compensation on an advisory (non-binding) basis.
Atea Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of the earnings press release issued on May 14, 2024.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024.
- Filing date: May 14, 2024.
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
Atea Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the three months and full year ended December 31, 2023. The filing serves as a formal vehicle to furnish the company's earnings press release.
📋 Key Facts
- Report date: February 28, 2024
- Reporting period: Three months and full year ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 regarding financial results.